Background/Aims: Recently, studies have shown that interleukin-37 (IL-37) is involved in atherosclerosis-related diseases. However, the regulatory mechanisms of IL-37 in atherosclerosis remain unknown. This study aims to determine the role of IL-37 in atherosclerosis and to investigate the underlying mechanisms involved. Methods: IL-37 expression in human atherosclerotic plaques was detected by immunohistochemical staining and real-time reverse transcription polymerase chain reaction (RT-PCR). Oil Red O staining was used to measure the size of plaques. Cell apoptosis in vitro and in vivo was tested by flow cytometric analysis and terminal deoxynucleotidyl-transferase mediated dUTP nick-end labeling (TUNEL) staining, respectively. Protein expression levels of IL-37, IL-18Rα and p-Smad3 were measured by Weston blotting. Results: Immunohistochemical staining revealed that IL-37 was highly expressed in human atherosclerotic plaques. Intracellular cytokine staining revealed that infiltrated CD4 + T lymphocytes and vascular smooth muscle cells (VSMCs), but not macrophages, were the major sources of IL-37. Mice that overexpressed IL-37 exhibited significant improvements in their atherosclerotic burden, as demonstrated by reduced plaque size, increased collagen levels, and reduced numbers of apoptotic cells in vivo. Subsequently, mechanistic studies showed that IL-37 played an anti-atherosclerotic role, at least partially, through reducing inflammation by
Introduction
Atherosclerosis is a chronic inflammatory disease of the arterial walls that is characterized by the generation and release of various inflammatory cytokines [1] . The initiation and progression of atherosclerotic inflammation involve complex cellular networks, and the major contributors of these networks are endothelial cells (ECs), monocyte-derived macrophages, T lymphocytes and vascular smooth muscle cells (VSMCs) [1, 2] . An interaction between Gremlin-1 and migration inhibitory factor (MIF) reduces the release of pro-inflammatory cytokines, thus influencing plaque vulnerability [3] . Previous studies have detected the presence of numerous cytokines, both pro-and anti-inflammatory, in atherosclerotic plaques, and a balance between the activities of these opposing cytokines has been shown to regulate disease severity [4, 5] .
Interleukin (IL)-37 is the 7th factor (IL-1F7) of the interleukin-1 family. IL-37 includes five structurally related isoforms (a-e), including the most functional isoform IL-37b [6] . Studies have indicated that the IL-37 gene is located in a region of human chromosome 2 but is absent in mice, as no genomic sequence corresponding to human IL-37 has been found in mice so far [6, 7] . Multiple cell types produce IL-37, including monocytes, tissue macrophages, synovial cells, tonsillar B cells, plasma cells, dendritic cells (DCs), epithelial cells and memory T cells [8] [9] [10] [11] [12] . IL-37 acts on a variety of these cells through its extracellular receptor IL-18 receptor α (IL-18Rα). IL-37 first binds to IL-18Rα, and subsequently recruits the orphan IL-1 receptor 8 (IL-1R8; formerly TIR8 or SIGIRR) in order to function as an inhibitor. The interaction between IL-37, IL-18Rα and IL-1R8 activates the nuclear translocation of IL-37, which leads to the downstream activation of a nuclear transcription factor termed mothers against decapentaplegic homolog 3 (Smad3); Smad3 activation then affects downstream gene transcription to exert biological effects [8, 12, 13] .
An increasing amount of evidence demonstrates that IL-37 plays an important role in regulating inflammatory and autoimmune diseases [14, 15] , including psoriasis [11] , obesity [16] , dextran sulfate sodium (DSS)-induced colitis [17] , liver inflammatory injury [18] , rheumatoid arthritis [19] and myocardial ischemia/reperfusion injury [20] . Recently, IL-37 was found to attenuate atherosclerosis in ApoE -/-mice with diabetes [21] ; however, the effect of IL-37 on the formation of atherosclerotic plaques in ApoE -/-mice and the underlying regulatory mechanisms of this process remain unknown.
In this study, we investigated whether IL-37 was involved in the progression of atherosclerosis, and most importantly, we explored the associated regulatory mechanisms of IL-37 function. We demonstrate, for the first time, that IL-37 is largely produced by CD4+ T cells and VSMCs and that it plays a protective role in atherosclerosis by promoting the differentiation of T helper (Th) cells into the anti-inflammatory phenotype; in doing so, this protein possesses the capacity to strengthen plaque stability by decreasing matrix metalloproteinase (MMP)-dependent degradation of collagen and suppressing SMC apoptosis.
Materials and Methods

Ethics statement
All clinical investigations in this study were performed according to the principles outlined in the Declaration of Helsinki and supported by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology. All patients provided informed consent. All animal experiments in 
Mice
Generation of IL-37tg mice. To investigate the role of IL-37 in atherosclerosis in mice, we generated IL-37-transgenic (IL-37tg) mice. To begin with, we constructed the IL-37b expressing plasmid. Human IL37b cDNA (NCBI: NM_014439.3) was inserted into a pIRES vector with a GFP expression sequence under a constitutively active CMV promoter. Next, fertilized eggs obtained from C57BL/6 background mice were injected with the pIRES IL-37b expression plasmid described above and then implanted into C57BL/6 females to generate IL-37 founders. Male founders were mated with C57BL/6 wild-type females. To ensure success of transgenic mice construction, we created four founders at first, but used one founder line in this study. Then IL-37tg mice were identified using genotyping PCR for IL-37b gene expression, which was performed on tails that were obtained from mice aged 3 to 4 weeks old. PCR was performed using the following primers: IL-37 F: 5'-GCCCTGAGCAAAGACCCCAA-3' and IL-37 R: 5'-TTTTCACTGCATTCTAGT TGTGG-3'. The PCR product produced by IL-37tg mice was 205 bp long. IL-37b protein expression was analyzed using western blot analysis, and the cytokine levels in the peripheral circulation were tested using ELISA. PCR-negative littermates and wild-type (WT) mice were used as controls.
C57BL/6 and ApoE -/-mice. Male C57BL/6 and ApoE -/-mice aged 6-8 weeks old and weighing 20-25 g were purchased from Beijing University (Beijing, China). The mice were maintained in a specific pathogenfree facility on a 12 h light: 12 h dark cycle at 25°C. The C57BL/6 and ApoE -/-mice were fed a chow diet or a high-fat diet (a Western type diet contain 0.15% cholesterol and 21% fat). All animals were cared for in accordance with NIH guidelines, and all animal studies were supported by the Animal Care and Utilization Committee of Huazhong University of Science and Technology. On the day of sacrifice, all animals were anesthetized intraperitoneally using sodium pentobarbital (50 mg/kg) and subsequently euthanized via cervical dislocation. Blood was then drawn from the ventricles, and plasma was isolated to analyze cholesterol and cytokine levels. Hearts, aortas, femurs and tibias were excised and placed in PBS for the following experiments.
Smad3 knock-out mice. Heterozygous Smad3 knock-out (Smad3 +/-) mice were generously supplied by Prof. Xiao Yang (Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China) [22] . Smad3 +/-mice were mated with IL-37tg-ApoE -/-mice to generate IL-37tg-ApoE -/-Smad3 +/-mice. IL-37tg-ApoE -/-Smad3 +/-females were then mated with IL-37tg-ApoE -/-Smad3 +/-males to generate the IL-37tg-ApoE -/-Smad3 -/-mice that were used in the in vivo experiments. After 6 generations, we obtained the IL-37tg-ApoE -/-Smad3 -/-mice with a C57BL/6 background that were used in this research project.
Human tissue specimens
The clinical portion of this investigation was performed according to the standards of the Declaration of Helsinki. The experiment was supported by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, and all selected patients provided written informed consent. In this study, fifteen human vascular specimens were isolated from fifteen different patients undergoing heart transplantation in the Department of Vascular Surgery, Union Hospital. Vascular specimens containing atherosclerotic plaques (n=7) from patients with a history of coronary heart disease were obtained and regarded as the experimental group after anatomical analysis. Normal vessels (n=8) without atherosclerotic plaques from patients without a history of angiosclerosis were used as the reference material in the control group. After surgery, the tissues were halved at the site of the maximum artery diameter. One half was fixed in formalin and embedded in paraffin for histological analysis, while the other half was immediately frozen at -80°C for subsequent western blot or RT-PCR analysis.
Treatment and groups
To test the expression of IL-37 in IL-37tg mice, ApoE -/-and IL-37tg-ApoE -/-mice were fed a standard diet or a Western diet for 16 weeks (n=6-8 per group). To directly investigate the role of IL-37 in atherosclerosis in mice, ApoE -/-and IL-37tg mice, both in a C57BL/6 background, were crossbred for three generations to generate IL-37tg-ApoE -/-mice. Mice were used in experiments when they were 12 weeks old. To induce atherosclerosis, the experimental group IL37tg-ApoE -/-mice (n=10) and control group ApoE -/-mice (n=10) were fed a high-fat diet (a HFD or Western type diet that contained 0.15% cholesterol and 21% fat) for 16 weeks beginning at the age of 8 weeks old.
To analyze effects on the signaling molecules IL-18Rα and Smad3, the experiments were divided into 2 parts: an IL-18Rα neutralization study and a Smad3 knock-out study. First, for the IL-18Rα neutralization study, the mice were randomly divided into 2 groups: IL-37tg-ApoE -/-mice that were treated with control IgG (n=6) or 100 μg of mouse anti-mouse IL-18Rα neutralizing mAb (R&D, USA) that was dissolved in 0.3 ml PBS. The mice were injected weekly according to the manufacturer's instructions for 12 weeks. Second, for the Smad3 knock-out study, the mice were also divided into 2 groups: IL-37tg-ApoE -/-Smad3 +/+ (n=6) and IL-37tg-ApoE -/-Smad3 -/-(n=6) mice. All animals were cared for in accordance with the NIH guidelines, and all animal studies were supported by the Animal Care and Utilization Committee of Huazhong University of Science and Technology.
En face lesion analysis and Oil red O staining
The aortic tree was dissected, opened longitudinally, and stained with 5% oil red O (Sigma, USA) for 30 minutes. Then, whole vascular specimens were washed ´3 times (for 15 seconds each) in running distilled water. Finally, the aortas were pinned down and photographed using a digital camera to acquire images of the en face lesion. The lesion area (as a percentage of the total area) was calculated using Image-Pro Plus 6.0.
Aortic root lesions analysis of Oil red O staining
The heart and aortic root were removed, fixed in 4% paraformaldehyde for 2 hours, and placed in a solution of 30% sucrose in PBS overnight at 4°C. Then, the hearts were embedded in optimum cutting temperature (OCT) compound and frozen at -80°C. Successive 6-8 μm transverse sections of the aortic root were obtained. Six to ten sections per mouse were stained with oil red O to calculate the average plaque area. Frozen sections were stained in 5% oil red O for 30 minutes. Then, the sections were washed ´3 times (for 15 seconds each) in running distilled water. Finally, the sections were stained for 3-5 seconds in Mayer's hematoxylin and rinsed with distilled water. The area of the plaque was measured using Image-Pro Plus 6.0.
Immunohistochemistry (IHC) and Immunofluorescence (IF)
To analyze of IL-37 expression in human atherosclerotic plaques, the human atherosclerotic plaques sections were stained using a routine protocol with hematoxylin-eosin (HE) and then stained with antihuman IL-37 mAb (1:100, Abcam, cat#ab116282, UK). The reaction products were visualized by treating the slides with 3, 30-diaminobenzidine tetra hydrochloride and then counterstaining them with hematoxylin. For the control slides, the primary antibody was replaced with PBS.
To analyze IL-37-expressing cells in human atherosclerotic plaques, immunofluorescence was performed using specific antibodies to identify Th cells (CD4, 1:50, Biolegend, cat#300502, USA), macrophages (CD68, 1:100, Santa Cruz Biotechnology, cat#sc-17832, USA), smooth muscle cells (a-SMA, 1:200, Abcam, cat#ab5694, UK) and endothelial cells (CD31, 1:100, eBioscience, cat#14-0319, USA). Then, the sections were probed using the relevant secondary antibodies, which were conjugated to peroxidaselabeled dextran polymer and visualized using a DAB system. Appropriate negative controls were used to ensure antibody specificity.
Masson and TUNEL staining
Meanwhile, we performed Masson's trichrome and Sirius red staining according to standard protocols to determine the collagen content in lesions. In addition, apoptotic cells in the intima were assessed using TUNEL staining with a Cell Death Detection Kit (Roche, Switzerland) according to the manufacturer's instructions. The results were analyzed using Image-Pro Plus 6.0.
Atherosclerotic vessel infiltrating cell isolation and flow cytometry analysis
Atherosclerotic vessels were minced into 2-3 mm pieces and incubated for up to 2 hours at 37°C in a solution containing type I collagenase (3 mg/ml) and elastase (1 mg/ml) (Worthington Biomedical Corp) in Hank's Balanced Salt Solution (HBSS, Sigma Aldrich). After digestion, the aortic disaggregates were fetal calf serum (FCS) and then passed through a 40-μm filter before they were washes twice. The cells were then isolated using density gradient centrifugation in Ficoll-Paque Plus (MP Biomedicals, USA) according to the manufacturer's instructions [23] . To measure Th1, Th2, Th17 and Treg cell polarization in atherosclerotic plaque tissues, the cells were stained using cell surface markers in addition to various intracellular cytokines or transcription factors. Briefly, the harvested cells were stimulated with Cell Stimulation Cocktail (eBioscience, USA) at 37°C in 5% CO2 for 5 h before intracellular staining was performed. The cells were then stained with PE-cy5 anti-CD4 (eBioscience, USA) for 30 min and washed with PBS. Then, the cells were fixed, permeabilized and stained with PE anti-IFN-γ, PE-anti-IL-4, and PE anti-IL-17A (eBioscience, USA).
For the Treg cell analysis, the cells were initially stained with PE-cy5 anti-CD4 and APC anti-CD25 and then washed with PBS. Then, the cells were fixed, permeabilized and stained with PE anti-Foxp3 for staining (eBioscience, USA).
Human CD4+ T lymphocyte isolation and treatment
The clinical investigation described in this section was performed according to the standards of the Declaration of Helsinki. The experiment was approved by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology, and all selected volunteers provided written informed consent. For the in vitro polarization experiments, human peripheral blood mononuclear cells (PBMCs) were isolated from the whole blood of healthy volunteers using density gradient centrifugation in FicollPaque Plus (MP Biomedicals, USA) according to the manufacturer's instructions. Naive CD4+ T cells were enriched from human PBMCs using negative selection followed by a magnetically negative depletion protocol according to the manufacturer's instructions (Miltenyi Biotec, Germany). Naive CD4+ T cells were stimulated using plate-bound mouse anti-human CD3 monoclonal antibodies (mAb, 10ug/ml, eBioscience, USA) and soluble anti-CD28 mAb (3ug/ml, eBioscience, USA) in 48-well culture plates (1.0 x 106 cells/well) containing complete RPMI 1640 culture medium (Gibco, USA) supplemented with 10% heat-inactivated fetal calf serum (Gibco, USA) and 1% penicillin/streptomycin at 37°C with 5% CO2 to activate T-cell receptors (TCRs) . The polarizing cytokines were added as follows: IL-12 (20 ng/ml, Peprotech, USA) and anti-IL-4-neutralizing antibody (10 μg/ml) to induce Th1 differentiation; IL-4 (20 ng/ml, Peprotech, USA) and anti-IFN-γ-neutralizing antibody (10 μg/ml) to induce Th2 differentiation; IL-6 (50 ng/ml, Peprotech, USA), TGF-β1 (2 ng/ml, Peprotech, USA), anti-IFN-γ-neutralizing antibody (10 μg/ml) and anti-IL-4-neutralizing antibody (10 μg/ml) in addition to anti-TGF-β1-neutralizing antibody (2 μg/ml) t Th17 differentiation; and TGF-β1 (10 ng/ml, Peprotech, USA), anti-IFN-γ-neutralizing antibody (10 μg/ml), anti-IL-4-neutralizing antibody (10 μg/ml), anti-IL-6-neutralizing antibody (2 μg/ml) and anti-TGF-β1-neutralizing antibody (2 μg/ml) to induce Treg cell differentiation. The cells were cultured with or without rIL-37 (100ng/ml) for 1 day for RT-PCR analysis, 3 days for cytokine ELISA analysis, and 4 days for flow cytometry analysis [24] [25] [26] .
Flow cytometry analysis
To analyze Th1, Th2 and Th17 cells, the cells were stimulated with Cell Stimulation Cocktail (eBioscience, USA) at 37°C in 5% CO2 for 5 h before intracellular staining was performed. Subsequently, the cells were stained with FITC anti-human CD4 at 4°C for 30 min to complete surface staining. After they were fixated and permeabilized, the cells were subsequently stained with APC anti-human IFN-γ, PE anti-human IL-4, PerCP-Cy5.5 anti-human IL-17A antibodies, and isotype controls were used to confirm antibody specificity at 4°C for 30 min in the dark. For Tregs, the cells were incubated with FITC anti-human CD4 and APC antihuman CD25 antibodies at 4°C for 30 min in the dark to perform cell surface maker staining. After the cells were fixated and permeabilized according to the manufacturer's instructions, the cells were stained with PE-Cy5 anti-human Foxp3 antibodies to detect Tregs. All of the antibodies used in these experiments were acquired from eBioscience. The data were acquired using FACS (BD Bioscience) [24] .
Flow cytometry analysis of apoptosis
The human aortic smooth muscle cell line (HASMCs) was purchased from ScienCell (USA), and the cells were cultured in DMEM medium with high glucose containing 10% fetal calf serum (Gibco, USA) and 1% penicillin/streptomycin. Cell apoptosis was monitored using FACS analysis with a Flow cytometric apoptosis analysis Kit (eBioscience, Annexin V-FITC and Propidium Iodide staining) [27] . 
Cell transfection and culture
To further analyze the effect of IL-37 on HASMC apoptosis, we transfected siRNA to disrupt total IL-37 expression. Briefly, the cells were seeded at 0.5×106 cells/well in 24-well plates. After the cells were grown to 50-60% confluence, the cells were transfected with either Signal Silence Control siRNA (100 nM) or a specific Signal Silence® IL-37 siRNA I (100 nM, both obtained from Cell Signaling Technology, USA) using the HiPerFect® Transfection Reagent (QIAGEN, Germany) according to the manufacturer's instructions. After 24 h, the cells were harvested, and total IL-37 expression levels were determined using RT-PCR and western blot analysis. After 24 h, the cells received fresh medium, and were then used in the subsequent experiments.
Western blotting IL-37 expression was determined in CD4+ T lymphocytes, HASMCs, monocytes, HUVECs using an anti-human IL-37 antibody (1:1000, Abcam, UK). Caspase-3 expression was detected in cultured HASMCs using an anti-human Caspase-3 antibody (1:1000, Abcam, UK). Phosphorylated Smad3 and IL-18Rα levels were measured in atherosclerotic plaque tissues using specific antibodies for p-Smad3 (1:1000, Abcam, UK) and IL-18Rα (1:1000, Abcam, UK). Protein extracted from cells or tissues was separated on 10% SDSpolyacrylamide electrophoresis gels and then transferred to Polyvinylidene fluoride (PVDF) membranes. After the membranes were blocked in 5% non-fat milk in TBST for 2 h, they were incubated with the indicated primary antibodies at 4°C overnight followed by incubation with a HRP-conjugated secondary antibody (1:3000) for 2 h. The resulting bands were detected using super ECL reagent. β-actin (1:1000, Abcam, UK) and GAPDH (1:500, Abcam, UK) were used as the loading controls to normalize comparisons between samples.
Real-time PCR
Total RNA was extracted from cultured cells or tissues using Trizol (Takara, Japan) and then reversetranscribed into cDNA using a PrimeScript RT reagent kit (Takara, Japan) according to the manufacturer's instructions. The relative mRNA levels of target genes were quantified using SYBR Green Master Mix (Takara, Japan) with an ABI PRISM 7900 Sequence Detector system (Applied Biosystems, USA). Each reaction was performed in duplicate, and changes in relative gene expression levels were normalized to GAPDH or β-actin levels using the relative threshold cycle method. The primers used in this study are shown (for all online suppl. material, see www.karger.com/doi/10.1159/000487344) in Suppl. Table 1 .
Laser capture microdissection, RNA amplification, and RT-PCR Aortic root sections were stained for SMA (Ab) described above. Using these images as a guide, SMA+ regions were marked in serial section, and those regions were selectively subjected to laser capture using a PALM laser capture microdissection (LCM) machine [28] . RNA amplification and RT-PCR were performed according to the manufacturer's instructions described above. Specific primers used are documented online, (see online suppl. material) in Suppl. Table 1 .
ELISA
The cytokines IFN-γ, IL-4, IL-17A, and TGF-β were analyzed in CD4+ T lymphocytes using ELISA Kits (RayBiotech, USA). The expression of IL-37 was detected in the supernatants of T lymphocytes and mice sera using an IL-37 ELISA Kit (AdipoGen, USA) according to the manufacturer's instructions. Finally, absorbance was read at 450 nm.
Statistical analysis
Data representative of at least 3-4 independent experiments were expressed as the mean ±SD. Differences between two groups were evaluated using unpaired Student's t tests, and one-way ANOVA followed by a post hoc Student-Newmann-Keuls test, when necessary, was used to analyze multiple comparisons. All analyses were performed using SPSS 19.0, and P<0.05 was considered significant. To analyze the involvement of IL-37 in human atherosclerosis, we first determined protein and mRNA expression levels of IL-37 in human atherosclerotic plaques. Fifteen human coronary artery specimens were isolated from patients undergoing heart transplantation and were immunostained with a rabbit anti-human IL-37 antibody (Ab) or phosphate buffer solution (PBS). Atherosclerotic plaque samples from patients with a history of coronary heart disease were used as a positive experimental group. On the other hand, normal coronary artery specimens from patients without a history of angiosclerosis were used as a negative control. Overall, IL-37 protein was expressed at low levels in normal arteries (n=8) but at high levels in the intima and media of arteries with atherosclerotic plaques (n=7, Fig. 1A, B) . Next, real-time reverse transcription polymerase chain reaction (real-time RT-PCR) was performed to measure IL-37 mRNA expression levels in atherosclerotic lesion tissues. Similar to the results discovered through protein analyses, we found that the level of IL-37 mRNA was elevated in all atherosclerotic lesions but not in normal aortic segments (Fig. 1C) . These data indicate that IL-37 is highly expressed in human atherosclerotic plaques.
To identify which cells are responsible for the elevation of IL-37 in human atherosclerotic lesions, we performed double immunofluorescence on the major cell types involved in atherosclerotic development. Unexpectedly, we discovered that IL-37 was minimally expressed in CD68 + lesional macrophages and was even undetectable in CD31 + ECs. However, we found that most of the IL-37 signal was expressed in CD4+ T lymphocytes and SMA + SMCs in human atherosclerotic plaque sections (Fig. 1D ).
To further demonstrate that CD4 + T lymphocytes and SMCs are the cellular sources of IL-37, we used lipopolysaccharide (LPS) and oxidized low-density lipoprotein (ox-LDL), which are potent inducers of inflammatory injury, to stimulate freshly isolated human CD4 + T lymphocytes and human aortic smooth muscle cells (HASMCs). As previously observed in this study, low protein levels of IL-37 were detected before inflammatory stimulation. However, after treatment with LPS for 12 hours (12 h) or ox-LDL for 24 h, intracellular 
protein levels of IL-37 were almost 2-to 4-fold higher than those prior to stimulation (see online suppl. material, Suppl. Fig. 1A, B) . These results suggested that both CD4 + T cells and SMCs are cellular sources of IL-37. In parallel experiments, we stimulated freshly isolated monocytes and human umbilical vein endothelial cells (HUVECs) with LPS for 12 h and ox-LDL for 24 h. The results showed that IL-37 levels increased after inflammatory injury in monocytes but not in HUVECs (see online suppl. material, Suppl. Fig. 1C, D) , indicating that blood monocytes secrete IL-37, while ECs do not. Taken together, these results indicate that CD4 + T lymphocytes, VSMCs and blood monocytes produce IL-37 and that endothelial cells do not.
In summary, these data suggest that in human atherosclerotic plaques, CD4 + T lymphocytes and VSMCs are responsible for producing IL-37, monocyte-derived macrophages in plaques that infiltrate the intima produce less IL-37, and endothelial cells do not produce IL-37.
IL-37-transgenic mice are viable
To directly investigate the role of endogenous IL-37 in atherosclerosis in vivo, we generated IL-37-transgenic (IL-37tg) mice. IL-37b gene expression was examined using genotyping PCR ( Fig.  2A) . Protein and mRNA expression levels in different tissues were evaluated using western blot analysis and real-time RT-PCR in mice aged 6-8 weeks that were fed a standard diet. We found that IL-37 mRNA was expressed at low levels in spleen, thymus, liver, vessel, and kidney samples under control conditions, but that these levels could be increased in such tissues under atherosclerotic conditions (see online suppl. material, Suppl. Fig, 2A ). IL-37 protein was mainly expressed in spleen and thymus, which is a central lymphoid organ that contributes to T lymphocyte development (Fig. 2B) . These results suggested that IL-37 may be produced by immune-related tissues or cells, and that IL-37 may be associated with the regulation of immune responses. Phenotypic characteristics of the IL-37tg colony did not differ from wild-type mice with regards to growth, weight, fertility, survival, behavior and male-to-female ratio over many generations of observation.
Genetic overexpression of IL-37 attenuates atherosclerosis
To determine the involvement of IL-37 in atherosclerosis in transgenic mice, we crossbred IL-37tg mice with apolipoprotein E (ApoE)-deficient (ApoE -/-) mice to generate IL-37tg-ApoE -/-mice. These mice were fed a high fat diet (HFD, containing 0.15% cholesterol and 21% fat) for 16 weeks to induce the development of advanced plaques. We then tested IL-37 expression in plasma and aortic arches using ELISA and immunofluorescent staining. We found that plasma levels of IL-37 were considerably high in IL-37tg-ApoE -/-mice, but the plasma pool of IL-37 was absent in ApoE -/-mice (see online suppl. material, Suppl. Fig. 2B ). At the same time, after a 16-week HFD, the IL-37 protein levels in aortic arches were evident in IL-37tg-ApoE -/-mice (Supplementary Fig. 2C) .
Next, to verify that IL-37 protects against atherosclerosis in vivo, male mice were fed a HFD beginning at the age of 8 weeks and continuing for 16 weeks. After this HFD period, the atherosclerotic lesion size in the descending thoracic and abdominal aorta (Fig. 3A, B) and the aortic sinus (Fig. 3C, D) was considerably smaller in IL-37tg-ApoE -/-mice than that in ApoE -/-mice. There was no difference in the chow diet that was fed to these two mice groups (see online suppl. material, Suppl. Fig. 2D ). In addition, treating mice with the human IL-37 transgene did not alter plasma levels of cholesterol, triglycerides or glucose (Table  1) . These results confirm the notion that endogenous IL-37 plays a protective role against atherosclerosis in mice.
Neutralizing endogenous IL-18Rα or knockout of Smad3 reduces the anti-atherosclerotic activity of IL-37
Because previous studies have demonstrated the functional involvement of the IL-37-IL-18Rα interaction in activating the downstream transcription factor Smad3 in inflammatory diseases [8, 13] , it is reasonable to speculate that IL-37 plays an anti-inflammatory role during atherosclerosis through the IL-18Rα and Smad3 signaling pathway. To test this hypothesis, we first compared the expression levels of IL-18Rα and phosphorylated Smad3 (p-Smad3) in ApoE -/-and IL-37tg-ApoE -/-mice that were fed a HFD. Our results showed that IL-18Rα and p-Smad3 were both upregulated in IL-37tg-ApoE -/-mice (Fig. 4A) . Next, anti-IL-18Rα-neutralizing monoclonal antibodies (mAb) were used for 12 weeks to block endogenous IL-18Rα in IL-37tg-ApoE -/-mice. The results showed that the atherosclerotic plaque size was significantly larger in mice treated with IL-18Rα mAb than that in IL-37tg-ApoE -/-mice treated with control lgG (Fig. 4B, C) . Additionally, we generated IL-37tg-ApoE -/-Smad3 -/-and IL-37tg-ApoE -/-Smad3 +/+ mice and fed them a HFD for 12 weeks. As shown in Fig. 4D , E, the protective effect of IL-37 was reversed in vivo after Smad3 was knocked out. Taken together, these results indicate that IL-37 plays an anti-atherosclerotic role that is associated with the signaling molecules IL-18Rα and Smad3 in vivo. 
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
IL-37 strengthens plaque stability by reducing MMP-2/13-dependent collagen degradation
Collagen constitutes a major proportion of the extracellular matrix in atherosclerotic plaques. The degradation of the extracellular matrix by matrix metalloproteinases (MMPs), which were reported to be secreted by SMCs (SMA high ) and inflammatory cells such as macrophages, T cells and ECs (SMA low ) [29] , is thought to contribute to atherosclerotic plaque instability [30] . Therefore, to evaluate whether IL-37 affects atherosclerotic stability, we first measured the collagen content of atherosclerotic plaque sections in mice fed a HFD for 16 weeks. The results showed that the collagen content in IL-37tg-ApoE -/-mice was higher than that in ApoE -/-mice (Fig. 5A, B) . Next, to determine whether the elevated collagen content was the result of an increase in collagen production or a decrease in MMP-mediated collagen breakdown in the IL-37tg-ApoE -/-mice, we analyzed the mRNA expression of several collagen types and MMPs that have been reported to be essential for plaque stability. Unexpectedly, we found that the expression of collagen I/III/VIII were all unchanged in IL-37tg-ApoE -/-and ApoE -/-mice (Fig. 5C ). However, while the expression levels of MMP-2 and MMP-13 were reduced, MMP-1 and MMP-9 mRNA levels were not (Fig. 5D-F) . These results indicate that IL-37 induced the elevation of collagen content, at least partly, by reducing the degradation of collagen by MMP-2 and -13, and not by increasing the production of collagen in vivo.
IL-37 enhances plaque stability by suppressing SMC apoptosis SMC apoptosis also significantly contributes to plaque instability [31] . We previously demonstrated that SMCs in human atherosclerotic plaques secrete IL-37. Therefore, we hypothesized that IL-37 might be involved in SMC apoptosis. To test this hypothesis, we used a terminal deoxynucleotidyl-transferase mediated dUTP nick-end labeling (TUNEL) assay to examine atherosclerotic plaque sections obtained from different experimental groups after the mice were fed a HFD for 16 weeks. As shown in Fig. 6A and B, IL-37 overexpression resulted in a markedly smaller TUNEL-positive area than that observed in control mice, suggesting that IL-37 inhibits the extent of cell apoptosis in vivo. 
: IL-37 Attenuates Atherosclerosis
We next tested whether IL-37 directly induces SMC apoptosis in vitro. HASMCs were first treated with different concentrations of recombinant IL-37 (rIL-37) for 24 h. We found that the optimum concentration of IL-37 that induced a decrease in activated caspase-3 expression was 500 ng/mL (Fig. 6C) . In addition, the activated caspase-3, which was determined using western blot analysis, was concomitantly upregulated by the inflammatory cytokines interferon gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) but was downregulated by treatment with exogenous IL-37 (Fig. 6D) , suggesting that IL-37 might protect HASMCs against apoptosis. Meanwhile, to further verify that IL-37 suppresses SMC apoptosis, we next pretreated HASMCs with exogenous IL-37 or silenced endogenous IL-37 using IL-37 small interfering RNA (siRNA; siIL-37) before we administered positive stimulation. The HASMCs were then cultured with or without hydrogen peroxide (H 2 O 2 ) or the pro-inflammatory cytokines IFN-γ and TNF-α, which are potent inducers of apoptosis [27] . As expected, flow cytometric analysis showed that treatment with H 2 O 2 or IFN-γ and TNF-α increased the frequency of apoptotic SMCs. At the same time, incubation with IL-37 significantly reduced H 2 O 2 -induced or IFN-γ and TNF-α-induced apoptosis. However, silencing endogenous IL-37 reversed the anti-apoptotic effect of IL-37, whereas the scramble HASMCs were treated with H 2 O 2 (200 μM) or TNF-α (100 ng/ml) and IFN-γ (100 ng/ ml) for 36 h in the absence or presence of rIL-37 or after IL-37 was silenced using IL-37 siRNA (siIL-37). Then, the cells were harvested and stained using FITC-annexin V and propidium iodide (PI). Statistical analysis of data from 3-4 independent experiments. Scr indicates scramble siRNA, which served as a negative control. Data are presented as the mean ± SD. *p<0.05, **p<0.01, ***p<0.001.
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry siRNA had no such effect (Fig. 6E-F) . Taken together, these data indicate that treatment with exogenous IL-37 protects against HASMC apoptosis in vitro, whereas silencing endogenous IL-37 exacerbates apoptosis. In summary, our results indicate that IL-37 enhances plaque stability by suppressing SMC apoptosis.
IL-37 regulates CD4 + T cell subsets in vivo and in vitro CD4
+ T cells, including pro-inflammatory Th1 and Th17, anti-inflammatory Th2 and regulatory T (Treg) cell subtypes, effectively control atherosclerotic inflammation in plaque tissues [32] . Following our observation that IL-37 is mainly secreted by CD4 + T lymphocytes in human atherosclerotic plaques, we hypothesized that IL-37 might impact T lymphocyte functions during the progression of atherosclerosis. To test this hypothesis, we measured CD4 + T cell subsets in inflamed lesional tissues and spleen tissues using flow cytometry and real-time RT-PCR analysis. Flow cytometric analysis showed that IL-37tg-ApoE -/-mice had lower numbers of CD4 + IFN-γ + (Th1) cells but higher numbers of CD4 + IL-4 + (Th2) cells than ApoE -/-mice, whereas the balance between Th17 and Treg cells was not altered in the inflamed lesional tissues (Fig. 7A) . Subsequently, a similar phenomenon was observed using real-time RT-PCR detection methods. The mRNA expression levels of the Th1 cytokine IFN-γ and the transcription factor T-bet were significantly lower in IL-37tg-ApoE -/-mice than that in ApoE -/-mice. However, the mRNA levels of the Th2 cytokine IL-4 and the transcription factor GATA3 were higher in the IL-37tg-ApoE -/-mice than that in the control group. Furthermore, we noticed some differences in Th17 and Treg cells between the two groups, but these differences were not statistically significant (Fig. 7B-E) . Next, we analyzed the same target expression levels in spleen tissues. Unexpectedly, there was no significant difference in splenic T cell subsets between the two groups (see online suppl. material, Suppl. Fig. 3 ). These results Having shown that IL-37 plays an anti-atherosclerotic role and having explored the regulatory mechanisms that potentially underlie the role of IL-37 in atherosclerosis in mice, we next investigated whether IL-37 played the same protective role in humans. Human CD4 + T cells were stimulated with IL-12 (20 ng/ml) to induce Th1 cell differentiation, IL-4 (20 ng/ml) to induce Th2 cell differentiation, IL-6 (50 ng/ml) to induce Th17 cell differentiation, or TGF-β1 (2 ng/ml) to induce Treg cell differentiation. The cells were then treated with rIL-37 (100 ng/ml) or PBS in vitro. The numbers of CD4 + cells that expressed IFN-γ, IL-4 or IL-17A were then determined using flow cytometric analysis. As shown in Fig. 8A , the number of CD4 + cells that contained IFN-γ was decreased from 48.0% to 37.3% in cells exposed to rIL-37, and the number of IL-4 containing cells was increased from 7.3% to 12.5% after cells were treated with rIL-37. Furthermore, the number of CD4 + cells that contained IL-17A was decreased from 5.9% to 3.9%, while CD4
+ T cell expression was not changed in cells exposed to rIL-37 (see online suppl. material, Suppl. Fig. 4A, B) . Additionally, an analysis of the relative mRNA expression levels of cytokines in culture supernatants showed the same trend (Fig. 8B-D) . These data support our hypothesis that rIL-37 attenuates inflammation by promoting Th2 cell differentiation and reducing Th1 cell differentiation.
Discussion
Evidence from recent studies has suggested that IL-37 potentially has a protective role against atherosclerosis [21] . However, direct evidence showing that IL-37 reduces atherosclerosis is still lacking, and many key questions remains unanswered. For example, IL-37 was previously demonstrated to have anti-inflammatory effects in experimental models of LPS-induced shock [13] , diet-induced obesity [16] and DSS-induced colitis [17] . Moreover, IL-37 also has been demonstrated to exert a protective effect in ApoE-deficient diabetic mice [21] . This protection was observed in experiments in which human rIL-37 was injected weekly for a total of 16 weeks. Although its previously described protective role in atherosclerosis is consistent with our findings, some differences remain between these two studies. First, we used IL-37 transgenic mice instead of human rIL-37 injections. Second, Meng Chai et al. used an ApoE-deficient diabetic mouse model that was different from our ApoE-deficient mouse model. In addition, the most significant difference was that we sought to further elucidate the regulatory mechanism underlying the protective effect of IL-37 against atherosclerosis. Additionally, our findings reveal that IL-37 is also an important anti-inflammatory modulator during atherosclerosis-induced inflammation in humans. Our results show that IL-37 suppresses H 2 O 2 -or pro-inflammatory cytokine-induced HASMC apoptosis and decreases Th1 cell differentiation while increasing Th2 cell differentiation in human CD4 + T cells. These results suggest that targeting the IL-37 pathway may provide a new therapeutic strategy for treating human coronary artery disease. However, further studies are needed.
A growing body of evidence shows that IL-37 is involved in immune responses during inflammatory injury. Most importantly, our lab and another group demonstrated that the circulating levels of IL-37 were elevated in patients with unstable angina pectoris [33] . However, little was previously known regarding the role of IL-37 in human atherosclerotic plaques, and to our knowledge, we are the first group to report the expression of IL-37 in human atherosclerotic plaques. Here, we observed that IL-37 levels were higher in lesional sections than that in normal arteries, suggesting that IL-37 may be involved in atherosclerosis. Moreover, the observation that IL-37 is highly expressed in inflamed local atherosclerotic plaque tissues but not healthy tissues indicates that IL-37 may mediate a negative feedback mechanism during inflammation. It is not surprising that inflammation induces antiinflammatory mechanisms to limit damage. Moreover, this observation is consistent with previous discoveries in inflamed mucosae [10] , psoriatic lesions [11] , synovial tissues in rheumatoid arthritis [13] and adipose tissue [16] . These studies indicate that IL-37 expression is likely linked to inflamed tissues but not normal tissues. Otherwise, the antiinflammatory cytokines IL-10 [34] and IL-19 [35] were both reported to be expressed in human atherosclerotic plaques and were found to be associated with decreased signs of inflammation.
Although previous studies largely focused on IL-37 in monocytes [8, 36] , little is known regarding the relationship between IL-37 expression in T cells and SMCs. In our study, most IL-37 + cells were CD4 + T cells or α-SMA + SMCs but not monocyte-derived macrophages. These results differ from those showing that the IL-37-expressing cells detected in human peripheral blood mononuclear cells (PBMCs) are monocytes [8] . We speculate that this discrepancy may be the result of differences between disease models. To our knowledge, the secretory function of blood monocytes might be attenuated after they have infiltrated into endothelial tissues and becomed foam cells. Moreover, IL-37 was detected in intimal and medial SMCs in human arteries with atherosclerosis but not in normal arteries, which is consistent with the Th2-cytokine IL-9, the expression of which has not been found in immune cells or normal SMCs but has been show in injured SMCs [37] . Studies of IL-37-producing monocytes have guided the investigation of IL-37 in innate immune responses over the past decade [13] . However, whether IL-37 modulates adaptive immune responses is unknown. Notably, in the present study, the IL-37 that is produced by CD4 + T cells may act as a bridge between adaptive and innate immunity. In atherosclerotic plaques, the switch in CD4 + T cell phenotypes has been proposed to be an important regulatory mechanism for limiting plaque size [32] . There is solid evidence showing that Th1-driven responses are detrimental to the atherosclerotic process because of the expression of IFN-γ, TNF-α and other pro-inflammatory cytokines, while Th2-driven responses are considered to be beneficial because of the expression of anti-inflammatory cytokines, such as IL-4 and IL-5 as well as IL-13 [38, 39] . These data suggest that the Th1/Th2 cell imbalance plays an important role in the development of atherosclerosis. Thus, our data, which show that IL-37 induced a Th1-to-Th2 shift in local inflamed lesional tissues in vivo and in human CD4 + T cells in vitro, indicate that IL-37 reduces inflammation by inducing pro-inflammatory Th cells to differentiate into the alternative anti-inflammatory phenotype. Additionally, our study demonstrates that IL-37 induced shift in the Th1-to-Th2 ratio in local inflamed lesional tissues, but not in the spleen. This effect might be attributed to the expression pattern of IL-37 because the highest levels of IL-37 expression were observed in local inflamed tissues, while only low levels were observed in the spleen, which is a peripheral immune organ.
The rupture of human atherosclerotic plaques is the major cause of myocardial infarction and stroke [40] . Collagen and VSMCs form a protective fibrous cap over atherosclerotic plaques. Therefore, collagen degradation and VSMC apoptosis in the fibrous cap are thought to contribute to plaque instability [30, 31, 41] . To our knowledge, we are the first group to report that IL-37 can increase plaque stability. In our study, we demonstrated that the increased collagen content in the transgenic mice expressing human IL-37 was a result of a reduction in the degradation of collagen by MMP-2 and -13 rather than a result of a direct increase in collagen production in vivo. At the same time, we found that IL-37 also suppressed SMC apoptosis. Our results suggest that IL-37 may be a potential novel therapeutic target for increasing plaque stability in fibrous caps.
In the present study, we detected the expression of IL-37 in plaque tissues in humans and transgenic mice to answer the question of the origin of IL-37 in atherosclerotic plaques. We propose that there may be two ways for IL-37 to arrive in these plaques. One possibility is that lesional CD4 + T cells and SMCs produce IL-37 and form functional autocrine loops. Another possibility is that IL-37 is produced by thymus tissue and is secreted under inflammatory conditions, after which it can infiltrate into the endothelium via an unknown mechanism.
In conclusion, this study demonstrates that IL-37 is a potent inhibitor of adaptive immune responses and provides an important additional molecular mechanism by which IL-37 attenuates atherosclerosis. We have presented evidence showing that IL-37 is produced primarily by CD4 + T cells and VSMCs and that it plays a protective role in atherosclerotic injury, at least partially, by directing a switch in CD4 + T lymphocyte phenotypes in addition to directly regulating the expression of caspase-3 to reduce H 2 O 2 -and pro-inflammatoryinduced SMC apoptosis. These findings suggest that increasing the production of IL-37 may be beneficial for controlling inflammation associated with atherosclerosis.
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